Li-Fraumeni SyndromeReLFNCT04982744
Registry of Li Fraumeni and Li Fraumeni Like Syndromes
An observational study of Li-Fraumeni Syndrome and Li-Fraumeni-Like Syndrome, run by Istituto Ortopedico Rizzoli at 2 sites in Italy.
Trial summary
ReLF is a retrospective and prospective registry, finalized for care and research purposes. It is articulated in main sections - strongly related and mutually dependent on each other - corresponding to different data domains: personal information, clinical data, genetic data, genealogical data, surgeries, etc. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Li-Fraumeni Syndrome, Li-Fraumeni-Like Syndrome
- How many people
- 200 participants
- Where
- 2 sitesItaly
- Study dates
- 2 Jul 2020to Jul 2045
- How long will I take part?
- 10 Years
- Phase
- Observational
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- Child, Adult, Older adult
Study population: Patients affected by Li Fraumeni or Li Fraumeni Like syndromes
Who may be able to join
- All patients affected by Li Fraumeni or Li Fraumeni Like syndromes
Who cannot join
- Any condition unrelated to Li Fraumeni or Li Fraumeni Like syndromes
Trial locations and contacts
2 sites in 1 country. Contact the study team or a site near you to ask about taking part.
Italy2 sites, 2 recruiting
- Recruiting
Irccs Istituto Ortopedico Rizzoli
Bologna, Emilia-Romagna, 40136
Marina Mordenti, PhD, +39 051 6366062, registri.malattierare@ior.it
Marcella Lanza, PhD, +39 051 6366169, registri.malattierare@ior.it
- Enrolling by invitation
IRCCS Istituto Ortopedico Rizzoli
Bologna, Emilia-Romagna, 40136
About this study
Official title: Registry of Li Fraumeni and Li Fraumeni Like Syndromes That Collects Clinical, Functional, Genetic, Genealogical, Imaging, Surgical, Treatment, Quality of Life Data. Data is Linked to Patients' Biological Samples, When Available
ReLF is a retrospective and prospective registry, finalized for care and research purposes. It is articulated in main sections - strongly related and mutually dependent on each other - corresponding to different data domains: personal information, clinical data, genetic data, genealogical data, surgeries, etc. This approach has been developed to corroborate and integrate data from different resources and aspects of the diseases and to correlate genetic background and phenotypic outcomes, in order to better investigate diseases pathophysiology. Due to legal requirements, institutional directives and organizational issues, we are unable to include individuals residing outside Italy in the registry at this time. We are currently engaged in the preparation of a recruitment process for individuals residing outside Italy.
Read the detailed description
The traditional method of collecting patient information is often chaotic, inconvenient, and sometimes even unsafe, particularly when dealing with rare diseases. In 2020, the need to simplify the diagnostic process and to overcome the difficulties of data storage and analysis, led to the suggestion of implementing the Registry of Li Fraumeni and Li Fraumeni Like syndromes (ReLF).
The ReLF relies on an IT Platform named GeDI (Genotype-phenotype Data Integration platform). This solution, realized by a collaboration among Department of Rare Skeletal Disorders and a local software-house (Dilaxia Spa), is a GDPR-compliant, multi-client, web-accessible system and it has been designed according to current medical informatics standards (Orphacode, ICD-10, Human Genome Variants Society, Findability Accessibility Interoperability Reusability -FAIR- Principles). GeDI is continuously implemented to improve management of persons with Li Fraumeni and Li Fraumeni Like Syndromes and to help researchers in analyzing collected information. ReLF is articulated in main sections:
- Personal data: it comprises general information, birth details and residence data;
- Patient data: including the patients internal code, the hospital code and other patient details;
- Diagnostic Process: the diagnosis, the status (affected, suspected, etc.), age at diagnosis, comorbidities, allergies, etc.;
- Genogram: a tool for designing the family transmission of the disease, alongside information on the disease status of all relatives included;
- Clinical events: it records a long list of signs and symptoms as well as several additional items to describe the disease
- Genetic Analysis and Alteration: including analytical technique, sample information, analysis duration, etc. This section also comprises detailed information on any detected pathological variants (e.g. gene, international reference, DNA change, protein change, genomic position, etc.);
- Visits: this section includes visit type (genetic, orthopedic, rehabilitation, pediatric, etc.), the date of the visit, prescriptions, imaging, etc.;
- Treatments: this section comprises information of a wide range of treatments including pharmacological, devices, supplements, and other treatments such as psychological, nutritional, etc.;
- Surgeries: this section contains information on the type of surgeries, the age of the patients, the site/localization of the procedures, etc.
- Documents: this repository allow us to store all types of documents (radiological reports, imaging, consents, clinical reports, etc.);
- Consents: this section provides a comprehensive overview of all consents collected, including the collection date;
- Samples: this section includes information on the samples, like the type, date of collection, etc.
- PROs: this section collects information on patients reported outcomes such as the quality of life or ABC scale.
- Conditions
- Li-Fraumeni Syndrome, Li-Fraumeni-Like Syndrome
- Keywords
- Disease Registry, Natural History Study, Genotype-Phenotype Correlation, Disease Evolution
- Medical subject headings
- Li-Fraumeni Syndrome, Li-Fraumeni-Like Syndrome
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Patients affected by Li Fraumeni and Li Fraumeni Like syndromes | The group comprises all patients affected by Li Fraumeni and Li Fraumeni Like syndromes |
What is being measured
The primary outcome is the main question the study is designed to answer.
Natural History and Epidemiology
Assessment of epidemiological information. Anthropometric data: weight in kg, height in cm. In addition, weight and height will be combined to report BMI as kg/m^2 Clinical details of the tumor: site of the lesion, number of recurrence(s), presence/absence of metastasis, size of lesion in cm^3 Additional clinical data: type of surgery, age at surgery in years are updated at each follow up and retrospectively (when possible).
Clinical reports, medical charts and imaging are the primary source of data.
Measured: Since the disease is rare, the timeframe is strictly related to patients enrolment and consequently to amount of collected data. Considering the low prevalence of this disease, the time frame is up to 10 years.
Secondary outcomes (1)
Genotype-Phenotype Correlation
The secondary outcome comprises the correlation between genotype and phenotype. This includes, but is not limited to, clinical features and genetic background. This will be pursued using the information collected during visits and follow-ups and the genetic information resulting from molecular investigations.
Collection of genetics background (target gene, type of mutation, clinical significance are reported following HGVS nomenclature) and family history (in terms of inheritance by maternal or paternal line).
Anthropometric data (weight in kg, height in cm. In addition, weight and height will be combined to report BMI in kg/m^2), clinical details (site of the lesion, recurrence, metastasis), orthopedic and functional features are updated at each follow up.
Measured: The timeframe is strictly related to patients enrolment and consequently to amount of collected data. Considering the low prevalence of this disease, the time frame is up to 10 years.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Jul 2021
- Study start2 Jul 2020
- Primary completionJul 2030 (estimated)
- Study completionJul 2045 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Li-Fraumeni SyndromeStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Other
- Enrolment
- 200 participants (estimated)
- Target duration
- 10 Years
Sponsor and investigators
- Lead sponsor
- Istituto Ortopedico Rizzoli
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Luca Sangiorgi, Istituto Ortopedico Rizzoli
- Investigators
- Luca Sangiorgi, MSc, Principal investigator, Istituto Ortopedico Rizzoli
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04982744
- Sponsor's protocol ID
- 579/2020/Oss/IOR
- Acronym
- ReLF
- Status last verified
- Nov 2025
- First submitted
- 30 Jun 2021
- Last updated
- 20 Nov 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No